Categories: News

Vaccinex to Present at the Oppenheimer 31st Annual Healthcare Conference

ROCHESTER, N.Y., March 11, 2021 (GLOBE NEWSWIRE) — Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, today announced that Dr. Maurice Zauderer, chief executive officer, will deliver a company presentation at the Oppenheimer 31st Annual Healthcare Conference, which is being held March 16-18, 2021.

Presentation details:
Date: Tuesday, March 16
Time: 2:30-3:00pm ET

A live webcast of the presentation is available at the following link during and following the conference: https://wsw.com/webcast/oppenheimer9/register.aspx?conf=oppenheimer9&page=vcnx&url=https://wsw.com/webcast/oppenheimer9/vcnx/2754411

About Vaccinex, Inc.
Vaccinex, Inc. is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The Company’s lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that prevents immune infiltration into tumors and triggers chronic inflammation in the brain. The Company additionally intends to leverage its proprietary drug discovery platform, ActivMAb®, to create opportunities for future pipeline expansion and strategic collaborations, particularly by exploiting its unique capability to select high value antibodies against difficult and important multi-pass membrane receptors including GPCR and ion channels.

Investor Contact                                        
Jeremy Feffer                                        
LifeSci Advisors, LLC                                
212-915-2568                                        
jeremy@lifesciadvisors.com

Staff

Recent Posts

CBIH Welcomes Federal Momentum Toward Cannabis Rescheduling as 2026 Opens a New Window to Accelerate Medical Innovation and Growth, with CBIH Positioned to Capitalize on Emerging Opportunities

Houston, Texas--(Newsfile Corp. - December 22, 2025) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH) (CBIH) announces…

29 minutes ago

XRP Healthcare® Secures Global Trademark Protection at the Intersection of Healthcare Services and XRP-Powered Payments

Multi-jurisdiction trademark coverage reinforces XRP Healthcare's position across digital health, pharmacy networks, and XRP-based payment…

1 hour ago

Black Book Poll: “Governed AI” Emerges as the Deciding Factor in 2026 NHS Procurement

Respondents report approvals and evaluation readiness are now the bottlenecks driving demand for reusable safety…

1 hour ago

Hemogenyx Pharmaceuticals PLC Announces Update on Admission of Shares

LONDON, UK / ACCESS Newswire / December 22, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the…

1 hour ago

What Is the Best GLP-1 Supplement for Weight Loss? Industry Analysis Reveals Probiotic Akkermansia Formulas as Affordable Ozempic Alternatives

Health Journey Addresses 'Best GLP-1 Supplement' Question with Akkermansia-Based Formula Analysis as Six-Month Costs Compare…

22 hours ago